文献速递浆细胞疾病

多发性骨髓瘤中抗BCMA治疗的再次有效应用

Effective anti-BCMA retreatment in multiple myeloma.
PubMed 文献 · Blood Adv · 2021-01-01

本文报道2例多发性骨髓瘤患者序贯使用抗BCMA治疗(CAR-T、双特异性抗体、抗体药物偶联物),并平行监测BCMA表达和抗CAR抗体。结合近期临床研究数据,讨论抗BCMA治疗的不同耐药机制,包括抗原逃逸、BCMA脱落、抗药物抗体、T细胞耗竭和免疫抑制微环境,为序贯治疗策略提供指导。

要点

  • 抗BCMA治疗序贯使用可能有效,需平行监测BCMA表达和抗CAR抗体。
  • 耐药机制包括抗原逃逸、BCMA脱落、抗药物抗体、T细胞耗竭和免疫抑制微环境。
  • 了解耐药机制有助于指导抗BCMA序贯治疗策略。

核心结论

  • 抗BCMA治疗序贯使用在多发性骨髓瘤中可能有效,需结合耐药机制监测指导策略。

研究设计与样本

  • 病例报告:2例多发性骨髓瘤患者序贯使用抗BCMA治疗,平行监测BCMA表达和抗CAR抗体,并结合近期临床研究数据讨论耐药机制。

主要发现

  • 报道2例序贯使用抗BCMA治疗并平行监测BCMA表达和抗CAR抗体的病例。
  • 抗BCMA治疗耐药机制包括抗原逃逸、BCMA脱落、抗药物抗体、T细胞耗竭和免疫抑制微环境。

临床怎么用

  • 抗BCMA治疗序贯使用时,可平行监测BCMA表达和抗CAR抗体以指导治疗策略。
  • 了解抗原逃逸、BCMA脱落、抗药物抗体、T细胞耗竭和免疫抑制微环境等耐药机制有助于序贯治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The recent emergence of anti-B-cell maturation antigen (BCMA) therapies holds great promise in multiple myeloma (MM). These include chimeric antigen receptor (CAR) T cells, bispecific antibodies, and antibody-drug conjugates. Their development in clinical trials and further approval are changing the strategy for treating MM. Considering that a cure has not been reached, a central question in the coming years will be the possibility of using these therapies sequentially. Here, we report 2 cases of the serial use of anti-BCMA therapies with parallel monitoring of BCMA expression and anti-CAR antibodies. We further discuss recent data from clinical studies that have informed us about the different mechanisms of resistance to anti-BCMA therapies, including antigen escape, BCMA shedding, anti-drug antibodies, T-cell exhaustion, and the emergence of an immunosuppressive microenvironment. This knowledge will be essential to help guide the strategy of serial treatments with anti-BCMA therapies.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Gazeau N, Beauvais D, Yakoub-Agha I, et al. Effective anti-BCMA retreatment in multiple myeloma. Blood Adv. 2021. PMID: 34351389. doi:10.1182/bloodadvances.2021004176

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。